RT Journal Article
SR Electronic
T1 123I metaiodobenzylguanidine (MIBG) scintigraphy of retinoblastoma: preliminary experience.
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 146
OP 150
DO 10.1136/bjo.73.2.146
VO 73
IS 2
A1 J Bomanji
A1 J L Hungerford
A1 J E Kingston
A1 D A Levison
A1 K E Britton
YR 1989
UL http://bjo.bmj.com/content/73/2/146.abstract
AB 123I metaiodobenzylguanidine (MIBG) is a radiopharmaceutical used for imaging neural crest tumours. The possibility of using 123I MIBG for imaging retinoblastomas has been assessed in this pilot study. Ten patients were studied, nine with clinically and histologically proved retinoblastomas and one with Coats's disease. 123I MIBG scintigraphy correctly identified the neoplasm in eight patients but gave a negative result in two, one of whom had Coats's disease and the other a retinoblastoma which proved to be extensively necrotic on histological examination. These preliminary results suggest that 123I MIBG scintigraphy may have a role in differentiating retinoblastomas from lesions that simulate them.